Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

2150results about "Polypeptide with His-tag" patented technology

Recombinant humanized type iii collagen and preparation method therefor

A recombinant humanized collagen and a preparation method therefor. The recombinant humanized type III collagen can be efficiently and stably expressed in three expression systems of yeast, Escherichia coli, and CHO cells, and has the biological activity superior to that of a commercially available collagen product. The recombinant humanized type III collagen has structural characteristics and functional activity similar to those of a natural collagen, and thus has wide application prospects in biomedical materials, tissue engineering products, cosmetics, foods, health care products or drugs, medical instruments, medical cosmetology and the like.
Owner:YANTAI PATRONUS BIOTECH CO LTD +1

Fusion protein and application thereof in preparation of Brazilian sweet

The invention provides a fusion protein and application thereof in preparation of Brazilian sweet. The fusion protein comprises a tag protein and a Brazilian sweet protein which are connected by a linker; wherein the linker comprises an amino acid sequence as shown in SEQ ID NO: 1, and the amino acid sequence as shown in SEQ ID NO: 1 is directly connected with the Brazilian sweet protein. The invention also provides a preparation method of the Brazilian sweet protein. The preparation method comprises the following steps: treating the fusion protein by using TEV protease and obtaining the Brazilian sweet protein. Large-scale expression of the fusion protein and the brazitame protein is realized by utilizing an escherichia coli expression system, and the obtained brazitame protein can be correctly folded and has high sweetness.
Owner:HANGZHOU YANSHOU TECHNOLOGY CO LTD

Novel IGG proteases and methods of use thereof

Provided herein are novel immunoglobulin G (IgG) proteases and fusion proteins comprising the same. The IgG proteases find utility in methods of treating diseases mediated in whole or in part by pathogenic immunoglobulin G (IgG) antibodies, including methods for preventing or treating antibody-mediated rejection (AMR) of an organ allograft in an organ-transplant patient.
Owner:INSMED INC

Varicella-zoster virus gE fusion protein as well as preparation method and application thereof

The invention belongs to the field of biological medicines, and particularly relates to a varicella-zoster virus gE fusion protein as well as a preparation method and application thereof. The varicella-zoster virus gE fusion protein comprises an amino acid sequence as shown in SEQ ID NO: 1 and at least one of the following fragments: a signal peptide, a Foldon sequence, a Ferritin sequence and a His tag sequence, the signal peptide can improve the protein expression quantity, the Foldon sequence can improve the stability of the protein, the particle size of an antigen can be increased, the immunogenicity of the antigen can be improved, and the fusion protein can be used for preparing a medicine for treating the varicella-zoster virus gE fusion protein. The Ferritin sequence can enhance immune response, a vaccine prepared from the gE fusion protein has excellent immunogenicity, and compared with a commercially available vaccine Shingrix, higher humoral immunity and cellular immunity levels can be induced.
Owner:BEIJING HUANUOTAI BIOMEDICAL TECH CO LTD

Recombinant botulinum toxin and preparation method thereof

ActiveCN119859174ANervous disorderPeptide/protein ingredientsHeavy chainBotulinum toxin type
The invention relates to the technical field of a preparation method of a type A recombinant botulinum toxin, in particular to a type A botulinum toxin obtained by adopting a gene recombination technology, and the amino acid sequence of the type A botulinum toxin is consistent with the sequence of the type A botulinum toxin prepared by extracting and purifying a wild strain Clostridium botulinum. According to the technical scheme, the single-chain protein of the botulinum toxin A sequentially comprises a botulinum toxin A light chain or a modified botulinum toxin A light chain, a connecting region and a botulinum toxin A heavy chain. According to the scheme, the high-quality recombinant botulinum toxin A is obtained after the single-chain protein is subjected to fermentation, crude purification, enzyme digestion and fine purification. According to the technical scheme, the problems of complex process, long period, high safety risk and the like in the existing process for preparing the botulinum toxin A from the wild bacterial strain clostridium botulinum can be solved, and meanwhile, the problem that the amino acid sequence consistent with that of the botulinum toxin A prepared from the wild bacterial strain clostridium botulinum cannot be obtained through the existing gene recombination technology is solved.
Owner:LEPU JIANTANG PHARMACEUTICAL (CHONGQING) CO LTD

Recombinant CD47 binding proteins and their use

PCT designated stage expiredWO2024251695A1Immunoglobulin superfamilyAntibody mimetics/scaffoldsDiseaseAnkyrin Repeat Protein
The present invention relates to recombinant binding proteins comprising a designed ankyrin repeat domain with binding specificity for CD47. In addition, the invention relates to nucleic acids encoding such recombinant binding proteins, pharmaceutical compositions comprising such recombinant binding proteins or nucleic acids, and the use of such recombinant binding proteins, nucleic acids or pharmaceutical compositions in methods of treating diseases, such as cancer, in a mammal, including a human.
Owner:MOLECULAR PARTNERS AG

Recombinant human-derived III-type collagen as well as preparation method and application thereof

The invention relates to the technical field of recombinant protein expression, in particular to recombinant human-derived III-type collagen as well as a preparation method and application thereof. The invention provides a recombinant human source III type collagen. The amino acid sequence of the recombinant human source III type collagen is shown as SEQ ID NO. 1. The recombinant human-derived III-type collagen prepared by the invention can be better applied to a human body, better exerts biological functions of the collagen, avoids repulsive interaction, is high in safety, can effectively promote cell proliferation and oxidation resistance, and is high in expression yield, stable in batches and good in quality; the recombinant human III type collagen prepared by the invention has the potential of being applied to preparation and production of biological medicines and cosmetics.
Owner:XINXIANG MEDICAL UNIV

Nerve nutrition composition for helping sleep and relieving depression

The invention provides a protein. The protein comprises an amino acid sequence as shown in SEQ ID NO: 1 or SEQ ID NO: 3. Corresponding nucleic acids, vectors, and compositions comprising the proteins are also provided. In some embodiments, the composition comprises recombinant collagen with an amino acid sequence as shown in SEQ ID NO: 1 or 3, gamma-aminobutyric acid, calcium gluconate, zinc gluconate, vitamin, oryzanol, recombinant humanized collagen with an amino acid sequence as shown in SEQ ID NO: 4 and cordyceps sinensis powder. The invention also provides application of the protein and the composition in preparation of products for helping sleep or relieving depression.
Owner:GUANGXI FULAIMING BIOPHARMACEUTICAL CO LED

Respiratory syncytial virus F protein mutant and application thereof

The invention belongs to the field of biological medicine, and particularly relates to a respiratory syncytial virus F protein mutant and application thereof. The respiratory syncytial virus F protein mutant is characterized in that at least one pair of amino acid residues in an F1 subunit and / or an F2 subunit of F protein polypeptide are substituted by cysteine, and / or an F protein signal peptide part is substituted by a human immunoglobulin light chain signal peptide, and / or alanine A at the 107 site of a multi-base sequence is mutated into arginine R, lysine K at the 134 site is mutated into arginine R, and the amino acid residues in the F1 subunit and / or the F2 subunit of the F protein polypeptide are mutated into arginine. According to the invention, more neutralizing antibody epitopes can be exposed, the stable pre-fusion conformation is maintained, effective neutralizing antibody reaction and antibody binding reaction to the RSV subtypes A and B can be ensured, and the vaccine is suitable for various vaccine forms taking the RSV F protein as the antigen.
Owner:BEIJING HUANUOTAI BIOMEDICAL TECH CO LTD

protease

PCT designated stage expiredWO2024246348A1Microorganism based processesDepsipeptidesBiochemistryProtease
The present invention relates to IgM specific proteases. Specifically, proteases according to the present invention are able to cleave IgM, including human IgM, with high specificity. The invention further relates to methods and uses of said proteases, particularly for the analysis and / or modification of IgM.
Owner:GENOVIS AB

Multi-effect repair type collagen and application thereof

The invention discloses a multi-effect repair type collagen and application thereof, and belongs to the technical field of synthetic biology. Transdermal peptide TD-1, a transmembrane region of human XVII type collagen, an extracellular sixteenth non-collagen region, an extracellular fifteenth collagen region and a coding gene of a His tag are selected to be connected in series, and a gene sequence is optimized through pichia pastoris codon selection preference; and then the T-COL17R3 is constructed and expressed to obtain the T-COL17R3. Efficacy experiments prove that compared with similar products sold in the market, T-COL17R3 not only has excellent transdermal performance, but also has better cell proliferation and migration promoting capability, better capability of resisting early saccharification product ketoamine and later saccharification product dicarbonyl compounds, better capability of scavenging free radicals and resisting elastase, and can be used for preparing the anti-epidermal drug. In addition, synthesis of melanin in B16-F10 cells can be reduced, so that T-COL17R3 has excellent application potential in development of pharmaceutical compositions or skin care products with repairing, anti-wrinkle and firming or whitening and brightening effects.
Owner:INST OF ADVANCED TECH UNIV OF SCI & TECH OF CHINA +1

Recombinant Humanized Collagen Type I Alpha-1 (rhCol1A1), and Expression Vector and Use Thereof

A recombinant humanized collagen type I alpha-1 (rhCol1A1), and an expression vector and use thereof are provided, belonging to the technical field of bioengineering. The rhCol1A1 has an amino acid sequence of SEQ ID NO: 1. This aim is to solve the problem of difficulty in expressing soluble full-length humanized collagen in Escherichia coli prokaryotic expression systems, and differences between the recombinant collagen and humanized collagen in yeast expression systems. It is proposed that the rhCol1A1 chain is expressed in Expi293F human embryonic kidney cells, and the protein expression level is increased using a fusion expression plasmid, enabling the expression of full-length humanized collagen type I alpha 1 chain. Activity studies have shown that the expressed rhCol1A1 exhibits a desirable activity in promoting cell migration, and may be widely used in the fields of biomedicine, tissue engineering, skin care, and food.
Owner:SHANDONG D-NUTRIMEC BIOMEDICAL CO LTD

Weed control methods and related compositions and plants

The present disclosure relates to, inter alia, a weed control method. In one example, a method comprises applying to the locus a weed controlling amount of a pesticide composition comprising a FatA acyl-ACP thioesterase-inhibiting herbicide, wherein the crop plants are modified such that they comprise a FatA acyl-ACP thioesterase which provides the crop plant with tolerance against the FatA acyl-ACP thioesterase-inhibiting herbicide. Recombinant polynucleotides and suitable for use in the methods, and edited FatA acyl-ACP thioesterases are also disclosed.
Owner:SYNGENTA CROP PROTECITON AG

Albumin binding proteins and methods of use

Provided herein are albumin binding proteins and methods of making and using thereof.
Owner:PARAGON THERAPEUTICS INC

Composition for detecting NAD < + > and application thereof

The invention specifically discloses a composition for detecting NAD < + > and application thereof, and relates to the technical field of biological detection. According to the composition for detecting NAD < + >, the composition comprises an NAD < + > binding protein fragment A connected with an Fc tag, an NAD < + > binding protein fragment B and a connecting peptide, the detection result is accurate and reliable, and meanwhile the technical difficulty, uncertainty and high cost faced by antibody screening in a traditional method are avoided.
Owner:HEFEI KNATURE BIO PHARM CO LTD

Pseudorabies virus gD recombinant protein, subunit vaccine as well as preparation method and application of pseudorabies virus gD recombinant protein and subunit vaccine

The invention relates to the technical field of biology, in particular to a pseudorabies virus gD recombinant protein, a subunit vaccine and a preparation method and application thereof.The gD recombinant protein sequentially comprises a signal peptide, a connecting peptide, the 21st-350th site of the gD protein, an enzyme cutting site and a His tag from the N end to the C end, the amino acid sequence of the 21st-350th site of the gD protein is shown as SEQ ID No.4, and the amino acid sequence of the 21st-350th site of the gD protein is shown as SEQ ID No.6. The pseudorabies virus gD recombinant protein has high immunogenicity, the prepared subunit vaccine can generate a specific antibody with neutralizing activity, mice do not die after challenge, the protection rate is 100%, the protection rate after challenge of pigs is 100%, pathological sections only show slight pathological changes, and the pseudorabies virus gD recombinant protein has wide application prospects.
Owner:HARBIN VETERINARY RESEARCH INSTITUTE CHINESE ACADEMY OF AGRICULTURAL SCIENCES (CHINA ANIMAL HEALTH & EPIDEMIOLOGY CENTER HARBIN BRANCH CENTER)

Chimeric antigen receptors targeting BCMA and methods of use thereof

The present application provides single-domain antibodies targeting BCMA, and chimeric antigen receptors (such as monovalent CAR, and multivalent CAR including bi-epitope CAR) comprising one or more anti-BCMA single-domain antibodies. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.
Owner:LEGEND BIOTECH USA INC

Albumin binding proteins and methods of use

Provided herein are albumin binding proteins and methods of making and using thereof.
Owner:PARAGON THERAPEUTICS INC

Mycoplasma hyopneumoniae recombinant antigen, expression vector, recombinant bacterium and application

PendingCN119264265ABacterial antigen ingredientsAntibacterial agentsAntigenImmune Response Process
The invention belongs to the technical field of medical biology, and particularly discloses a mycoplasma hyopneumoniae recombinant antigen, an expression vector, a recombinant bacterium and application. The invention provides a construction method of a mycoplasma hyopneumoniae recombinant antigen, which is characterized in that a mycoplasma hyopneumoniae P97 protein R1 region is modified to construct the mycoplasma hyopneumoniae recombinant antigen as shown in SEQ ID No.1. The mycoplasma hyopneumoniae recombinant antigen is cloned into an expression vector, and a recombinant engineering bacterium is obtained by using a genetic transformation means. The recombinant engineering bacterium can stably express the recombinant antigen of the mycoplasma hyopneumoniae, can be prepared into an oral living bacterium preparation, has the characteristics of safety, effectiveness, rapidness and the like, and particularly can prevent infection of the mycoplasma hyopneumoniae to pigs without an immune response process.
Owner:CHANGSHA LVYE BIOTECHNOLOGY CO LTD +1

Antibody binding to human CD73, preparation method therefor, and use thereof

The present invention provides an antibody binding to human CD73, a preparation method therefor, and a use thereof. The monoclonal antibody of the present invention can bind to a CD73 antigen with high specificity, has high affinity, has remarkable anti-tumor activity and the like, and has excellent clinical application prospects.
Owner:SUNSHINE GUOJIAN PHARMA (SHANGHAI) CO LTD

Recombinant fusion protein of respiratory syncytial virus of prefusion conformation and preparation method and application of recombinant fusion protein

The present invention relates to a respiratory syncytial virus subtype B (RSV-B) recombinant F protein, a polynucleotide encoding the same, a nucleic acid construct comprising the polynucleotide, an expression vector comprising the nucleic acid construct, a host cell wherein the polynucleotide, the nucleic acid construct or the expression vector is transformed or transfected, a stabilized trimer formed therefrom, and a method for preparing the same. An immunogenic composition comprising any of the foregoing, and its use in the preparation of a vaccine for the prevention and / or treatment of respiratory syncytial virus infection. The RSV-B recombinant F protein comprises at least one specific epitope of the pre-fusion F protein, a stable F protein tripolymer with pre-fusion conformation can be formed, the expression is stable, the form is uniform, and the yield is greatly improved; the formed F protein trimer has good immunogenicity, can stimulate an organism to generate high-level antibody titer, and has great significance in clinical treatment and prevention and control of the respiratory syncytial virus.
Owner:BEIJING BENEWILL TECH DEV CO LTD

Anti-LYPD3 antibody

The present invention relates to anti-LYPD3 antibodies that bind to LYPD3 in an O-glycosylation dependent manner. Therefore, the antibody has specificity to tumor-associated LYPD3 (LYPD3). The invention also provides a pharmaceutical composition containing the anti-LYPD3 antibody and an application of the pharmaceutical composition in cancer treatment.
Owner:FUNDIS SHAFAM JOINT CO

Fusion protein capable of generating point mutation in cells, preparation and use thereof

The present invention relates to a fusion protein that produces point mutations in cells, its preparation and use. Specifically, the fusion protein provided by the present invention contains a Cas enzyme that lacks cytosine deaminase and nuclease activity and retains helicase activity, or is formed by a Cas enzyme that lacks cytosine deaminase and nuclease activity and retains helicase activity. The present invention also relates to the coding sequence of the fusion protein, a polynucleotide sequence containing the coding sequence, a nucleic acid construct containing the polynucleotide sequence, a corresponding host cell, a method for producing point mutations in a cell, and a kit, etc. By using the present invention, it is possible to achieve site-directed mutagenesis while obtaining high mutation efficiency and a variety of mutation combinations in a specific gene region.
Owner:SHANGHAI INST OF BIOLOGICAL SCI CHINESE ACAD OF SCI

Honey truffle sweetener (HTS) variants

Fungal sweet-taste modifying protein variants (designated Honey Truffle Sweetener (HTS) protein variants), and polynucleotides encoding the protein variants are described. Specifically, Myd (HTS) protein variants with sweet taste modulation activity, and the cDNA encoding the same, are described, along with methods for isolating such cDNA and for isolating and expressing such proteins. Also disclosed are sweetening compositions which include the proteins of the invention, and methods to provide improved flavor to a product for oral administration.
Owner:MYCOTECHNOLOGY INC

Hemonchus contortus subunit vaccine

The invention discloses a haemonchus contortus subunit vaccine, and belongs to the field of veterinary vaccines. The subunit vaccine comprises an antigen protein MEP3, an antigen protein AP1, an antigen protein AP8, an antigen protein H11-2, an antigen protein H11-4 and an antigen protein AP5 of galactosylated and modified haemonchus contortus, and the antigen protein MEP3, the antigen protein AP1, the antigen protein AP8, the antigen protein H11-2, the antigen protein H11-4 and the antigen protein AP5 of galactosylated and modified haemonchus contortus. The galactosylation modification of the antigen protein is realized by jointly expressing glycosyl transferase HcGALT of haemonchus contortus and one or more of the proteins in eukaryotic cells. The antigen protein modified by galactosylation in the subunit vaccine is closer to the glycosylation modification of natural protein, and can provide effective immune protection after the goat is infected with haemonchus contortus, and the egg laying rate is reduced by 81.43%. The invention lays a foundation for development of haemonchus contortus subunit vaccines, provides an effective technical means for prevention and treatment of the haemonchus contortus subunit vaccines, and has important application value and popularization prospect.
Owner:HUAZHONG AGRI UNIV

System and method for detecting toxin activity

The invention provides a system and a method for detecting toxin activity. The system comprises one or more of the following components: HEPES, NaCl, DTT, a surfactant or Zn (OAc) 2. According to the present invention, the enzyme digestion is performed on the toxin (such as meat toxin), in the system, the enzyme activity determination of the toxin is more convenient by using the fluorescence resonance energy transfer (FRET) method, the high-flux determination of the activity of the toxin can be achieved by using the method, and the determination is more efficient and accurate.
Owner:YSTE (HAINAN) AESTHETIC MEDICINE HEALTH TECH CO LTD +1

Recombinant fusion antibody, and antibody-drug conjugate and use thereof

Disclosed are a recombinant fusion antibody, and an antibody-drug conjugate and use thereof. The recombinant fusion antibody includes an antibody, at least one lysosome-targeting peptide, and at least one linker peptide, wherein the antibody is fused with the lysosome-targeting peptide to form the recombinant fusion antibody via the linker peptide; wherein the lysosome-targeting peptide is at least one selected from the group consisting of a lysosome-sorting signal peptide from a Golgi-localized, γ-adaptin ear-containing, ARF-binding protein (GGA), a lysosome-sorting signal peptide from a mannose 6-phosphate receptor (MPR), a lysosome-sorting signal peptide from a lysosome-associated membrane protein (LAMP), and a variant; wherein the variant is a peptide with one or more amino acids substituted, deleted, and / or added when aligned with the lysosome-sorting signal peptide from a GGA, a MPR or a LAMP. Compared with the original antibody, the internalization and lysosomal trafficking ability of the recombinant fusion antibody are significantly improved.
Owner:SUN YAT SEN UNIV

A low molecular weight collagen with a 164.88° triple helix structure

Provided is a low molecular weight collagen with a 164.88° triple helix structure. Relates to a small molecule collagen, a preparation method and use thereof. The collagen of the present application comprises an amino acid sequence as shown in SEQ ID NO:1 or a variant amino acid sequence after mutation of the amino acid sequence, and the variant amino acid sequence retains the function of the amino acid sequence as shown in SEQ ID NO:1. The amino acid sequence of the collagen of the present application is shorter and has better transdermal absorption performance.
Owner:SHANXI JINBO BIO PHARMACEUTICAL CO LTD